Introduction {#s1}
============

PD is a common neurodegenerative disease with clinical heterogeneity and diverse causative factors. At least nine genes have been implicated in PD, with overlapping pathological features ([@B1]). The common *LRRK2* G2019S mutation is located in the kinase domain, possibly associated with an increase in kinase activity ([@B2]). Clinically, patients harboring G2019S share considerable similarity with sporadic PD patients ([@B3]). The polymorphic variants G2385R, R1628P, and S1647T are associated with increased risk for PD in the Asian population ([@B4]).

A recent study showed that PD patients with the Asian *LRRK2* variants experienced greater progression in motor symptoms ([@B5]). However, other aspects of the disease, including non-motor symptoms which greatly account for the decline of quality of life in PD, were not evaluated during the follow-up. To address this gap in knowledge, we conducted a longitudinal study to evaluate the progression of both motor and non-motor features in Asian *LRRK2* PD carriers compared to non-carriers.

Methods {#s2}
=======

Study Population
----------------

PD patients were assessed prospectively from movement disorder outpatient clinics in Singapore General Hospital over a 4-year period. The clinical diagnosis was based on the UK PD Brain Bank criteria ([@B6]). PD patients who received deep brain stimulation surgery or whose PD diagnosis was amended during the follow-up period were excluded. Our study was approved by SingHealth Centralized Institutional Review Board, and all methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all subjects.

Genetic Analyses and Grouping Patients
--------------------------------------

Three *LRRK2* variants (R1628P, S1647T, and G2385R) were genotyped by TaqMan real-time PCR. Based on the genotyping results, we grouped the patients into *LRRK2* risk variant carriers (R1628P, S1647T, and/or G2385R missense variants) and non-carriers (wild type for all the *LRRK2* variants).

Data Collection and Assessments
-------------------------------

Demographic data were collected from all subjects. The levodopa equivalent daily dose was calculated by standardized formula ([@B7]). Modified Hoehn and Yahr (H&Y) staging scale, Unified Parkinson\'s Disease Rating Scale (UPDRS) part III, Non-motor Symptom Scale (NMSS), Parkinson\'s disease Questionnaire-39 item version (PDQ-39), and Elderly Cognitive Assessment Questionnaire were applied to assess disease severity, motor symptoms, non-motor burden, quality of life, and cognitive impairment, respectively. UPDRS scores were obtained during the "on" medication period. There are nine domains in NMSS, including cardiovascular domain, sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous ([@B8]). The overall non-motor burden (NMSS total score) is calculated by the sum of all the domain scores. PDQ-39 comprises 39 questions categorized in 8 domains (mobility, activities of daily living, emotional well-being, stigma, social support, cognitive impairment, communication, and bodily discomfort). Summary index (SI) is calculated for the total PDQ-39 scale (PDQ-39 SI) and the eight domains. A higher NMSS score and PDQ-39 SI indicate greater NMS burden and worse quality of life. A lower Elderly Cognitive Assessment Questionnaire score suggests greater cognitive impairment. The assessments were conducted by one clinical research staff with formalized training on the same day at baseline and follow-up visits. The follow-up visits were carried out yearly, and the final visit was up to 4 years. Both the rater and patients were blinded to genotype status.

Statistical Analysis
--------------------

Frequency together with proportion was reported for categorical data, while median together with interquartile range was reported for continuous variables at baseline. Fisher\'s exact test was performed to compare categorical data at baseline among different groups of patients, while the Mann--Whitney test was carried out to compare the distribution of these continuous variables between different groups of patients. The differences from baseline in patients with risk variants were compared to the control group by means of generalized estimating equation model. Each score was standardized; an interaction term between visit and group was examined for its significance by means of GEE model. Data analysis was performed in Stata V13.1 (Stata Corp, College Station, TX, USA) and R 3.1.3 ([www.r-project.org](https://www.r-project.org)) with significance level of 5%.

Results {#s3}
=======

A total of 202 PD patients, including 133 patients with risk variants and 69 controls without risk variants, were assessed prospectively over a 4-year period. One hundred thirty-three patients carried at least one of the three risk variants. The G2385R frequency was 6.8% (17 patients), the R1628P frequency was 8.4% (21 patients), while the S1647T frequency was 53.0% (132 patients). At baseline, there were no significant differences in the demographic characteristics, UPDRS score, and NMSS score between risk variant carriers and non-carriers ([Table 1](#T1){ref-type="table"}).

###### 

Comparison of demographic and baseline clinical data between two groups.

  ----------------------------------------------------------------------------------------
                                  **Non-carriers**\   **Risk variants**\   ***P*-value**
                                  **(*n* = 69)**      **(*n* = 133)**      
  ------------------------------- ------------------- -------------------- ---------------
  Age of onset                    57.5 (50, 64.5)     60 (53, 66)          0.3549

  Gender                                                                   0.2867

  Male                            39 (56.5%)          86 (64.7%)           

  Female                          30 (43.5%)          47 (35.3%)           

  Ethnicity                                                                0.5691

  Chinese                         60 (87%)            120 (90.2%)          

  Non-Chinese                     9 (13%)             13 (9.8%)            

  PD family history                                                        0.1247

  No                              66 (95.7%)          117 (88.0%)          

  Yes                             3 (4.3%)            16 (12.0%)           

  Young onset                                                              0.5712

  No                              54 (79.4%)          109 (82.6%)          

  Yes                             14 (20.6%)          23 (17.4%)           

  Disease duration                5 (3, 8)            6 (3, 9)             0.2767

  Education years                 8.6 ± 5.0           8.3 ± 4.8            0.1730

  LEDD (mg/day)                   300 (150, 540)      399 (200, 550)       0.4021

  UPDRS total score               28 (10, 36)         29 (19, 38)          0.1780

  UPDRS tremor score              1 (0, 3)            2 (0, 4.5)           0.4662

  UPDRS postural and gait score   4 (2, 6)            4 (3, 6)             0.2616

  H&Y \[median (IQR)\]            2.5 (1.5, 2.5)      2.5 (2, 2.5)         0.1747

  NMSS total score                22 (12, 44)         26 (14, 52)          0.2048

  ADL scale                       90 (80, 90)         80 (70, 90)          0.0874

  HAMD                            5 (2, 7)            4 (2, 9)             0.8217
  ----------------------------------------------------------------------------------------

*LEDD, levodopa equivalent daily dose; UPDRS, Unified Parkinson\'s Disease Rating Scale; NMS, non-motor symptom; H&Y, Hoehn and Yahr staging scale; IQR, interquartile range; ADL scale, Schwab and England activities of daily living scale; HAMD, Hamilton Depression Rating Scale; PD Family History, patients have positive family history of Parkinson\'s disease; Young onset, onset age of PD patients is \<50 years old*.

GEE model analysis showed that mean H&Y scale increased more substantially after 4 years onwards in patients with risk variants (risk variants carriers, 0.65; non-carriers, 0.06, *P* = 0.041). Consistently, risk variant carriers showed faster progression of UPDRS postural and gait score than non-carriers from baseline to year 4 follow-up (visit 5), although the differences were not significant (risk variants carriers, 0.83; non-carriers, 0.54, *P* = 0.348) ([Table 2](#T2){ref-type="table"}, [Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}).

###### 

Comparison of mean change from baseline in selected parameters between two groups by generalized estimating equation (GEE) model.

  **Time period**                                 **Non-carriers**       **Risk variants**     ***P*-value**
  ----------------------------------------------- ---------------------- --------------------- ---------------
  **Standardized UPDRS total score**                                                           
  Change at visit 2                               −0.30 (−0.68, 0.07)    −0.02 (−0.25, 0.21)   0.202
  Change at visit 3                               0.07 (−0.19, 0.34)     0.09 (−0.06, 0.24)    0.910
  Change at visit 4                               0.40 (0.17, 0.62)      0.43 (0.21, 0.64)     0.797
  Change at visit 5                               0.69 (0.31, 1.07)      0.71 (0.34, 1.07)     0.945
  **Standardized UPDRS posture and gait score**                                                
  Change at visit 2                               −0.21 (−0.56, 0.15)    −0.09 (−0.34, 0.16)   0.582
  Change at visit 3                               0 (−0.28, 0.28)        0.10 (−0.06, 0.27)    0.538
  Change at visit 4                               0.17 (−0.10, 0.44)     0.37 (0.09, 0.66)     0.278
  Change at visit 5                               0.54 (0.13, 0.94)      0.83 (0.38, 1.28)     0.348
  **Standardized H&Y scale**                                                                   
  Change at visit 2                               0.04 (−0.19, 0.27)     0.08 (−0.14, 0.31)    0.800
  Change at visit 3                               0 (−0.23, 0.23)        −0.04 (−0.21, 0.13)   0.803
  Change at visit 4                               0.14 (−0.25, 0.53)     0.20 (−0.1, 0.50)     0.835
  Change at visit 5                               0.06 (−0.16, 0.29)     0.65 (0.13, 1.18)     **0.041**
  **Standardized frequency of NMS**                                                            
  Change at visit 2                               −0.65 (−0.95, −0.34)   −0.16 (−0.48, 0.16)   **0.035**
  Change at visit 3                               −0.14 (−0.45, 0.18)    0.08 (−0.12, 0.28)    0.269
  Change at visit 4                               0.57 (0.23, 0.91)      0.51 (0.28, 0.74)     0.772
  Change at visit 5                               0.95 (0.51, 1.39)      0.94 (0.50, 1.38)     0.952
  **Standardized NMSS domain 3 score**                                                         
  Change at visit 2                               −0.51 (−0.76, −0.26)   −0.15 (−0.39, 0.08)   **0.042**
  Change at visit 3                               −0.22 (−0.47, 0.03)    −0.2 (−0.38, −0.02)   0.879
  Change at visit 4                               0.39 (−0.22, 0.99)     0.33 (0.02, 0.64)     0.869
  Change at visit 5                               0.59 (0.14, 1.05)      1.09 (0.43, 1.75)     0.219
  **Standardized PDQ-39 domain 3 SI**                                                          
  Change at visit 2                               −0.25 (−0.51, 0.01)    0.21 (−0.11, 0.53)    **0.029**
  Change at visit 3                               0.04 (−0.23, 0.31)     0.07 (−0.15, 0.3)     0.853
  Change at visit 4                               0.65 (0.12, 1.18)      0.54 (0.22, 0.86)     0.729
  Change at visit 5                               1.06 (0.45, 1.68)      1.56 (0.9, 2.21)      0.286

*Vaues in bold indicate significant difference*.

*Frequency of NMS, total number of NMS items; NMSS domain 3, mood/apathy; PDQ-39, Parkinson\'s disease questionnaire-39 item version; PDQ-39 domain 3, emotional well-being*.
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In terms of non-motor symptoms, at year 1 follow-up (visit 2), scores of non-carriers in mean NMSS domain 3 score (mood/apathy), mean PDQ-39 domain 3 SI (emotional well-being), and total number of NMS items were simultaneously reduced. These score changes were significantly different between non-carriers and risk variant carriers ([Table 2](#T2){ref-type="table"}, [Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). However, the progression of non-motor symptoms was not significantly different after year 1 between the two groups.
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![Progression of Parkinson\'s disease Questionnaire-39 item version (PDQ-39) domain 3 score in two groups.](fneur-10-01379-g0004){#F4}

Discussion {#s4}
==========

Our long-term follow-up revealed greater disease severity after 4 years onwards using Modified H&Y staging scale, which grades the overall motor function of the patients. In particular, postural instability contributes significantly to the scores in H&Y staging ([@B9]). Consistently, the trend is notable that patients with risk variants in our study present with higher UPDRS postural and gait score compared with non-carriers, although there was no statistical significance probably due to limited sample size. It is also possible that risk variant carriers would show more substantial motor progression if the follow-up duration were to be extended. In line with our hypothesis, Oosterveld et al. reported that PD patients in another independent cohort who harbored the same *LRRK2* risk variant(s) presented greater motor progression after 4 years onwards ([@B5]). It was reported that *LRRK2* G2385R variant carriers presented more severe form of PD compared with G2019S and idiopathic PD patients ([@B10]). Therefore, specific *LRRK2* variants should be analyzed separately in clinical studies. However, it is not statistically feasible in our study due to insufficient subjects in each subgroup. In addition, when studying the effect of *LRRK2* variant on PD progression, it is optimal to examine the status of other PD-related genes, which may be associated with *LRRK2* and affect the risk of *LRRK2*-related PD, such as *SNCA* ([@B11]) and *GBA* ([@B3]).

In terms of non-motor symptoms and quality of life, transient differences were found in NMS total frequency, NMSS domain 3 (mood and apathy), and PDQ-39 domain 3 (emotional well-being) between non-carriers and risk variant carriers at early stage of the disease. This indicates progression course of non-motor symptoms and quality of life in PD with risk variants may differ from non-carriers. These non-motor symptoms may have to be identified and addressed timely in PD patients carrying risk variants.

Our current prospective study provides comprehensive information on the progression of multifaceted clinical features in PD with Asian-related risk variants, including motor, non-motor symptoms, and quality of life. Our study found that progression of motor symptoms became faster in risk variant carriers after 4 years, whereas progression of non-motor symptoms differed at early stage of disease between non-carriers and risk variant carriers, suggesting that *LRRK2* carriers may need to be closely monitored and managed for clinical progression.

We acknowledge that sample size may be a potential limitation in our study, which may increase the risk of false positive error. Validation of our findings in larger cohort will be warranted.
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